96 Tests PN: B411095

Components:

45x Ab-conjugated beads (S4P6 - NHP FGF basic Ab-bead). PN: B411095A. One vial containing 100 μL of anti-NHP FGF basic conjugated to AimPlex Bead S4P6.

25x Biotin-detection Ab (NHP FGF basic Biotin-dAb). PN: B411095B. One vial containing 100 μL of biotinylated anti-NHP FGF basic.

Lyophilized Standard - NHP FGF basic. PN: B411095S. One vial containing lyophilized recombinant FGF basic.

Application: Optimal antibody pair and antigen standard for assaying NHP FGF-basic/FGF-2. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

For Research Use Only. Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 20 pg/mL

  • Quantitation range:

  • LLOQ: < 30 pg/mL

  • ULOQ: > 10,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

Basic fibroblast growth factor, also known as bFGF, FGF-2 or FGF-β, is a member of the fibroblast growth factor family. FGF-2 has been shown in preliminary animal studies to protect the heart from injury associated with a heart attack, reducing tissue death and promoting improved function after reperfusion. Recent evidence has shown that low levels of FGF2 play a key role in the incidence of excessive anxiety. Additionally, FGF-2 is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. Diseases associated with FGF2 include chronic myocardial ischemia and intravascular papillary endothelial hyperplasia.

References:

  1. Kim HS (1998). "Assignment1 of the human basic fibroblast growth factor gene FGF2 to chromosome 4 band q26 by radiation hybrid mapping". Cytogenetics and Cell Genetics 83 (1-2): 73. doi:10.1159/000015129. PMID 9925931.

  2. Kühn MC, Willenberg HS, Schott M, Papewalis C, Stumpf U, Flohé S, Scherbaum WA, Schinner S (Feb 2012). "Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation". Molecular and Cellular Endocrinology 349 (2): 180–8. doi:10.1016/j.mce.2011.10.018. PMID 22040599.

  3. House SL, Bolte C, Zhou M, Doetschman T, Klevitsky R, Newman G, Schultz Jel J (Dec 2003). "Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia". Circulation 108 (25): 3140–8.

  4. Pereira RC, Economides AN, Canalis E (Dec 2000). "Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts". Endocrinology 141 (12): 4558–63. doi:10.1210/en.141.12.4558. PMID 11108268.